Phase II preoperative pembrolizumab for MSI high or MSS/PD-L1 gastric cancer followed by surgery and adjuvant therapy with pembrolizumab (NCT03257163): Results of a multicenter study

被引：0
|
作者：
Kennedy, Timothy
Shah, Mihir Maheshkumar
Kabarriti, Rafi
Boland, Patrick M.
In, Haejin
Chen, Chunxia
Szabo, Stephen M.
Hochster, Howard S.
Moore, Dirk F.
Jabbour, Salma K.
机构：
[1] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
[2] Emory Univ, Winship Canc Inst, Dept Surg, Div Surg Oncol, Atlanta, GA USA
[3] Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY USA
[4] Rutgers Sch Publ Hlth, New Brunswick, NJ USA
[5] Emory Univ, Duluth, GA USA
[6] Rutgers Canc Inst, New Brunswick, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.441
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：441 / 441
页数：1
相关论文
共 50 条
  • [21] Efficacy and Safety Results From the NeoPembrOV Study, a Randomized Phase 2 Trial of Neoadjuvant Chemotherapy With or Without Pembrolizumab Followed by Interval Debulking Surgery and Standard Systemic Therapy ± Pembrolizumab for Advanced High-Grade Serous Carcinoma: a GINECO Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (08) : 19 - 20
  • [22] Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non–small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study
    Hayato Kawachi
    Motohiro Tamiya
    Akihiro Tamiya
    Seigo Ishii
    Katsuya Hirano
    Hirotaka Matsumoto
    Yasushi Fukuda
    Toshihide Yokoyama
    Ryota Kominami
    Daichi Fujimoto
    Kazutaka Hosoya
    Hidekazu Suzuki
    Tomonori Hirashima
    Masaki Kanazu
    Nobuhiko Sawa
    Junji Uchida
    Mitsunori Morita
    Takeshi Makio
    Satoshi Hara
    Toru Kumagai
    Investigational New Drugs, 2020, 38 : 211 - 218
  • [23] A multicenter randomized phase III trial of neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy in resectable gastric cancer: First results from the CRITICS study
    Verheij, Marcel
    Jansen, Edwin P. M.
    Cats, Annemieke
    van Grieken, Nicole C. T.
    Aaronson, Neil K.
    Boot, Henk
    Lind, Pehr A.
    Kranenbarg, Elma Meershoek-Klein
    Nordsmark, Marianne
    Putter, Hein
    Trip, Anouk Kirsten
    van Sandick, Johanna W.
    Sikorska, Karolina
    van Tinteren, Harm
    Van de Velde, Cornelis J. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [24] A multicenter randomized phase III trial of neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy in resectable gastric cancer: first results from the CRITICS study
    Verheij, M.
    Cats, A.
    Edwin, P. M. Jansen
    Nicole, C. T. van Grieken
    Neil, K. Aaronson
    Boot, H.
    Pehr, A. Lind
    Kranenbarg, E. Meershoek-Klein
    Nordsmark, M.
    Putter, H.
    van Tinteren, H.
    Cornelis, J. H. Van De Velde
    ANNALS OF ONCOLOGY, 2016, 27 : 140 - 140
  • [25] A Randomized Phase III Study of Pembrolizumab Versus Pembrolizumab-Carboplatin-Pemetrexed for Locally Advanced or Metastatic Nonsquamous Non-small-cell Lung Cancer with PD-L1 50% or more (LAPLACE-50): Study Protocol
    Kogure, Yoshihito
    Hashimoto, Hiroya
    Oki, Masahide
    CLINICAL LUNG CANCER, 2021, 22 (06) : E921 - E924
  • [26] A randomized phase 2 trial of the IO102-IO103 (IDO and PD-L1) cancer vaccine plus pembrolizumab as neoadjuvant/adjuvant treatment of patients with solid tumors.
    Long, Georgina V.
    Haddad, Robert I.
    Robert, Caroline
    Mortier, Laurent
    Schadendorf, Dirk
    Uppaluri, Ravindra
    Svane, Inge Marie
    Saiag, Philippe
    Lim, Annette May Ling
    Rivas, Ainara Soria
    Scolyer, Richard A.
    Chaney, Marya F.
    Abildgaard, Cecilie
    Ahmad, Qasim
    Ringeisen, Francois Philippe
    McDowell, Diane Opatt
    Burtness, Barbara
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [27] Phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+HER2-breast cancer :KEYNOTE-756
    Cardoso, Fatima
    O'Shaughnessy, Joyce
    McArthur, Heather
    Schmid, Peter
    Cortes, Javier
    Harheck, Nadia
    Telli, Melinda L.
    Cescon, David W.
    Fasching, Peter A.
    Shao, Zhimin
    Loirat, Delphine
    Park, Yeon Hee
    Gonzalez Fernandez, Manuel
    Rubovszky, Gabor
    Im, Seock-Ah
    Hui, Rina
    Takano, Toshimi
    Andre, Fabrice
    Yasojima, Hiroyuki
    Liu, Zhenzhen
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (01) : S4 - S5
  • [28] TACTI-002: A Phase II Study of Eftilagimod Alpha (Soluble LAG-3) & Pembrolizumab in 2nd line PD-1/PD-L1 Refractory Metastatic NSCLC
    Forster, M.
    Krebs, M.
    Majem, M.
    Peguero, J.
    Clay, T.
    Felip, E.
    Iams, W.
    Roxburgh, P.
    Doger, B.
    Bajaj, P.
    Kefas, J.
    Scott, J. A.
    Joaquin, A. Barba
    Mueller, C.
    Triebel, F.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S395 - S395
  • [29] Phase Ib/II, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naive to anti-PD-1 therapy
    Long, G. V.
    Milhem, M.
    Amin, A.
    Hoimes, C. J.
    Medina, T.
    Conry, R. M.
    Lao, C.
    Daniels, G.
    Reddy, S.
    Mehmi, I.
    Andtbacka, R. H. I.
    Barve, M.
    Shaheen, M.
    Tueting, T.
    Chisamore, M.
    Xing, B.
    Candia, A.
    Gamelin, E.
    Janssen, R.
    Ribas, A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [30] Efficacy and safety of capmatinib plus pembrolizumab in treatment (tx)-naive patients with advanced non-small cell lung cancer (NSCLC) with high tumor PD-L1 expression: Results of a randomized, open-label, multicenter, phase 2 study.
    Mok, Tony S. K.
    Luigi Cortinovis, Diego
    Majem, Margarita
    Lynne Johnson, Melissa
    Ingriani Mardjuadi, Feby
    Zhao, Xuan
    Vidya Siripurapu, Sagar
    Jiang, Zhiqiang
    Wolf, Juergen
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345